Tetra Jumps on Cancer Drug Tests


It’s the very thing patients need to hear as Christmas time approaches; more developments were published today on the fight against cancer.

Ottawa-based Tetra Bio-Pharma Inc. (TSX-Venture: TBP) is trumpeting its status as a leader in cannabinoid-derived drug discovery and development. Tuesday, it announced it will be requesting a meeting with the U.S. Food and Drug Administration (FDA) to discuss the drug development program for its Orphan Drug candidate HCC011, inhaled delta-9-tetrahydrocannabinol (THC), in the treatment of hepatocellular carcinoma.


Hepatocellular carcinoma (HCC), also known as primary liver cancer, is the most common form of liver cancer and is responsible for 80% of the primary malignant liver tumors in adults. In addition to the quality of life benefits to cancer patients, based on preclinical research, HCC011 should also have anti-tumor effects.


Tuesday’s news release indicated the Phase 2 study of HCC011 will target patients with disease progression on Sorafenib, have measurable disease, and Child-Pugh Class A liver impairment.


The Phase 2 trial will consist of a single arm. Patients will receive the HCC011 by inhalation three times daily, in combination with Sorafenib, until disease progression or unacceptable toxicity.


Shares in TBP gained 2.5 cents, or 5.4%, to 48.5 cents, on volume of 434,000

Related posts

Carl Icahn Increases His Stake In Take-Two Interactive To 10.68%

ValueWalk

iPad Mini Display Outperformed By Kindle Fire HD & Nexus 7

ValueWalk

Foxconn Might Open Manufacturing Plants In The U.S. [REPORT]

ValueWalk

Peter Cundill Protégé Tim McElvaine on Investing in Japan [VIDEO]

ValueWalk

Set Bing Home Page Image As Lock Screen In Windows 8

ValueWalk

Morning Market News: JCP, APO, MCHP, ZIP, ENR, LGF, EA, ATVI, COV, LNT

ValueWalk